Checked.be
Active
BE 0894.208.059Private limited company
APOTHEEK JOHAN COPPENS
Antwerpsesteenweg 100 ·9000 Gent, Belgium· 18 yrs active
Sector: Retail sale of pharmaceutical products
(47730)
Conclusion
APOTHEEK JOHAN COPPENS has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €11k and a net result of €-42k. Equity is shrinking by ~37.3% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2026. Its solvency ranks better than 25% of 17366 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €11k |
| Net result | €-42k |
| Better than sector | 25% |
| Active | 18 yrs |
Financial profile
34
/ 100
Fragile profile, watch profitability in particular.
All 5 axes are computed from data Checked has read.
Health
22
Profitability
0
Solvency
15
Growth
32
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2007, 18 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
22
/ 100
Critical
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
No credit
negative equity or figures too weak
Score history
73
2022
81
2023
32
2024
22
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 1.03 (≥ 1.0)
+5
Leverage
Debt/equity 22.32 (> 3.0)
-10
Profitability
Negatieve ROE -391%
-10
Interest coverage
Interest coverage -170.0× (< 1.5×)
-10
Profit trend
Net profit down YoY
-3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 30-04-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining
At this pace, equity would indicatively turn negative around fiscal year 2026, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 47, Retail trade · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 4.3% | 34.6% | |
| Net result | €-42k | €5k | |
| Equity | €11k | €44k | |
| Gross operating margin | €83k | €34k | |
| Staff costs | €116k | €40k |
€-36k
-87.7%
22-25
€-42k
-62.5%
22-25
€-36k
-91.7%
22-25
€249k
+29.0%
22-25
€11k
-79.6%
22-25
€7k
-85.4%
22-25
1
-31.6%
22-25
€116k
+50.5%
22-25
€164
+3.2%
22-25
€238k
+69.5%
22-25
€226k
+76.4%
22-25
€10k
0.0%
22-25
1.03
-25.3%
22-25
0.63
-11.1%
22-25
4.3%
-84.2%
22-25
22.32
+732.6%
22-25
-391.1%
-698.1%
22-25
-16.8%
-26.0%
22-25
-170.02
-107.1%
22-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - |
| EBITDA | €-36k | €-19k | €34k | €57k |
| Net profit | €-42k | €-26k | €24k | €51k |
| Cash flow | €-36k | €-19k | €30k | €55k |
| Staff costs | €116k | €77k | €76k | €90k |
| Income taxes | €164 | €159 | €4k | €2k |
| Dividends | - | - | - | - |
| Total assets | €249k | €193k | €205k | €219k |
| Equity | €11k | €52k | €78k | €65k |
| Debt | €238k | €141k | €127k | €154k |
| of which ≤ 1y | €226k | €128k | €116k | €143k |
| of which > 1y | €10k | €10k | €10k | €10k |
| Working capital | €7k | €49k | €70k | €65k |
| Employees (FTE) | - | - | 1.3 | 1.9 |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 1.03 | 1.38 | 1.60 | 1.45 |
| Quick ratio | 0.63 | 0.71 | 0.91 | 0.94 |
| Working capital ratio | 2.9% | 25.3% | 34.2% | 29.7% |
| Solvency | 4.3% | 27.2% | 38.1% | 29.7% |
| Debt / equity | 22.32 | 2.68 | 1.62 | 2.36 |
| Long-term debt ratio | 0.94 | 0.19 | 0.13 | 0.15 |
| Interest coverage | -170.02 | -82.11 | 145.60 | 114.05 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | -16.8% | -13.3% | 11.5% | 23.2% |
| ROE | -391.1% | -49.0% | 30.1% | 78.1% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (25 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €249k | €193k | €205k | €219k |
| Fixed assets | 21/28 | €16k | €16k | €19k | €11k |
| Tangible fixed assets | 22/27 | €16k | €16k | €19k | €11k |
| Current assets | 29/58 | €233k | €177k | €186k | €208k |
| Stocks & contracts in progress | 3 | €90k | €86k | €81k | €74k |
| Amounts receivable within one year | 40/41 | €47k | €17k | €33k | €26k |
| Investments | 50/53 | €25k | - | - | - |
| Cash & bank | 54/58 | €32k | €42k | €46k | €81k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €249k | €193k | €205k | €219k |
| Equity | 10/15 | €11k | €52k | €78k | €65k |
| Contributions / capital | 10/11 | €78k | €78k | €78k | €78k |
| Reserves | 13 | €922 | €922 | €922 | €922 |
| Accumulated profits (losses) | 14 | €-68k | €-26k | €-796 | €-14k |
| Amounts payable | 17/49 | €238k | €141k | €127k | €154k |
| Amounts payable after one year | 17 | €10k | €10k | €10k | €10k |
| Amounts payable within one year | 42/48 | €226k | €128k | €116k | €143k |
| Trade debts payable within one year | 44 | €60k | €59k | €56k | €37k |
| Income statement | |||||
| Gross operating margin | 9900 | €83k | €61k | €112k | €149k |
| Operating result | 9901 | €-42k | €-26k | €27k | €52k |
| Financial income | 75 | €712 | €963 | €1k | €1k |
| Financial charges | 65 | €211 | €233 | €231 | €499 |
| Result before taxes | 9903 | €-42k | €-26k | €27k | €53k |
| Income taxes | 67/77 | €164 | €159 | €4k | €2k |
| Net result for the period | 9904 | €-42k | €-26k | €24k | €51k |
| Result to be appropriated | 9905 | €-42k | €-26k | €24k | €51k |
Legal Structure
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 14-12-2007 |
| Status | Active |
| Postal code | 9000 |
Establishment units
Antwerpsesteenweg 100, 9000 Gent
since 20082.167.933.964
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44804D0077/00G002 | Flanders | 319 m² | 1 · 319 m² | 19.2 m · 4 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
30-04
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
30-09
Financial
Weakest financial yearnet €-42k
Net result drops to €-42k, the lowest in the series.
24-03
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
24-04
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
06-04
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
28-03
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
27-04
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
28-04
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
02-04
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
27-04
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
28-04
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Retail sale of pharmaceutical products47730
Names & trade names
| Legal nameNL | APOTHEEK JOHAN COPPENS |
Similar companies
APOTHEEK PANORAMA BAAL
BE 0722.881.513 · Tremelo
PHARMACIE HERBAUX
BE 0863.014.245 · Silly
Pharmacie du Palais
BE 0899.955.508 · Thimister-Clermont
PHARMACIE DE BROUCKERE
BE 0881.900.640 · Brussel
PHARMELLE
BE 0760.602.338 · Aalst